OpenAlex
PricingAboutJobs
Log inGet started
Work

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

HTML

Year: 2020
Type: conference-abstract
Source: Blood
DOI: 10.1182/blood-2020-139457
Authors: Tommy Li, Ida H Hiemstra, Christopher Chiu, Roberto S Oliveri, Dena DeMarco, Theodora W. Salcedo, Frederikke Lihme Egerod, Manish Gupta
Institutions: Genmab (United States), Genmab (Netherlands), Genmab (Denmark)
Language: English

Topic: Monoclonal and Polyclonal Antibodies Research
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: epcoritamab, bispecific antibodies, recommended phase 2 dose, trimer formation, target engagement, hook effect, pharmacodynamic modeling, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, tumor response prediction, T cell dynamics, B cell dynamics, interindividual variability
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3094948272
Cites:
Cited by: 4
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security